Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3078 - 1,3,5 s-triazine containing analogues a prime Src family inhibitor: Design synthesis docking, anticarcinoma and angiogenic inhibition efficacy on cancer grafted CAM


11 Sep 2017


Poster display session


Cancer Biology


Prateek Pathak


Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361


P. Pathak1, A. Balkrishna2, P.K. Shukla1, V. Kumar1, A. Kumar3, A.K. Singh4, A. Verma1

Author affiliations

  • 1 Pharmaceutical Science, Sam Higginbottom Institute of Agriculture, Technology & Sciences, 211007 - Allahabad/IN
  • 2 Drug Design And Discovery, Patanjali Research Institute, 247405 - Haridwar/IN
  • 3 Pharmacy, SV Subharti University, Meerut/IN
  • 4 Clinical, ESIC, Delhi/IN


Abstract 3078


The importance of angiogenesis for solid tumor growth is well recognized and evident by the vast differential of research devoted to the subject for over thirty years. It is a complex process directed by growth factors, receptors, extracellular matrix (ECM)-to-cell and cellto- cell interactions. Tyrosine kinase (TKs) is the protein enzymes catalyze the transfer of a phosphate group from an ATP molecule to a tyrosine residue of the target protein, thus leading to signal transduction. Cytoplasmic TKs such as Src, Abl and Lck have been to date discovered and characterized and found that inhibition signalling pathway. A special Src protein like FAK is a non-receptor protein-tyrosine kinase which have vital role in various cellular function like cytoskeleton reorganization, migration, adhesion, spreading, configuration and destruction of FA, cell protrusions, progression, proliferation and apoptosis. The functional ateration of Src signal may be the reason for cancer and metastasis. So this can predict that Src and their signal inhibition can utilized in cancer therapy. Triazine containing hybrid analogues act as a prime skeleton to inhibit Src family TKs like FAK so in present project we constructed 1,3,5-triazine containing analogues (TCA) as an effective cancer induced angiogensis inhibitor.


TCA analogues constructed accordingly similarity field positioning and pattern through forge V10. Further more in-silico simulation was done using autodock for most prominent analogues. The analogues derived via multifactorial synthetic protocol. The activity evaluation proceeded via in-vitro assay against MCF-7 (Breast cancer) cell line and further in-ova antiangiogenic potency evaluated against cancer induced chick chorioallantoic membrane.


The newly designed and constructed TCA heterocycles expressed more than 56% of similar field point pattern and intra atomic alignments. The prominent pattern showed by the analogue 8d (chloro-anilino) and 8k (bromo-anilino). In-silico docking on hydrophobic site of Src family protein (PDB: 4BRX) revealed that analogue 8d have binding with CYS502, TR503, GLU506, ILE428, ASN551 while analogue 8k shoed interaction with THR503, GLU506, ILE428, LEU567, ASN551 amino acid residue which was similar like vendatinib. Biological evaluation showed that analogues 8d and 8k have great tendency to inhibit cancer induced angiogenesis with marginal toxicity profile.


We have developed a significant series of anticancer analogues and propound the site of binding on the surface of Src family TKs receptor FAK.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.